Dr. Goldstein on Mechanisms of Resistance to Endocrine Therapy

Lori J. Goldstein, MD
Published: Saturday, Jul 19, 2014

Lori Goldstein, MD, director, The Naomi and Phil Lippincott Breast Evaluation Center, deputy associate director, Clinical Research, Fox Chase Cancer Center, discusses mechanisms of resistance to endocrine therapy.

Some mechanisms of resistance to endocrine therapy have to do with ER co-regulation and downstream effects (signaling transduction interaction) with PI3K, AKT3, and MAPK. In her presentation at the 13th Annual International Congress on the Future of Breast Cancer®, Goldstein discussed new agents and new opportunities in this space: mTOR, HDAC, and CDK4/6 inhibitors.

Goldstein notes that there is also earlier data in the areas of SARC inhibition and androgen synthesis inhibition.
 
Lori Goldstein, MD, director, The Naomi and Phil Lippincott Breast Evaluation Center, deputy associate director, Clinical Research, Fox Chase Cancer Center, discusses mechanisms of resistance to endocrine therapy.

Some mechanisms of resistance to endocrine therapy have to do with ER co-regulation and downstream effects (signaling transduction interaction) with PI3K, AKT3, and MAPK. In her presentation at the 13th Annual International Congress on the Future of Breast Cancer®, Goldstein discussed new agents and new opportunities in this space: mTOR, HDAC, and CDK4/6 inhibitors.

Goldstein notes that there is also earlier data in the areas of SARC inhibition and androgen synthesis inhibition.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x